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ABSTRACT OF THESIS
TRENDS AND PATTERNS IN USE OF MEDICATIONS FOR OPIOID USE
DISORDER IN A COMMERCIALLY INSURED POPULATION IN THE U.S.
Opioid use disorder (OUD) and opioid overdose are pervasive public health
problems in the U.S. Medications for opioid use disorder (MOUD) have been shown
effective to reduce OUD morbidity and mortality. Two distinct approaches to MOUD are
currently used: agonist therapy (methadone or buprenorphine) or antagonist therapy
(naltrexone). Limited information is available about the patterns of use, adherence to
therapy, and characteristics of those who use agonist vs. antagonist therapy. The objective
of this study is to assess recent trends in MOUD, adherence in use of MOUD, and the
characteristics of those who use agonist vs. antagonist therapy in a nationally representative
population of commercially insured patients in the U.S.
This retrospective descriptive study utilized data from Truven Marketscan
Commercial Claims and Encounters database from years 2011 to 2016. All individuals
aged 18 years and older who have a diagnosis of OUD and utilize MOUD at any point
during the study period were included. Demographic characteristics of interest included
age, gender, geographic region, and type of insurance coverage. Clinical characteristics of
interest included diagnosis of OUD and type of MOUD used, including extended – release
naltrexone for injection, oral naltrexone, buprenorphine in combination with naloxone, and
buprenorphine alone. Descriptive analyses were employed to understand utilization
patterns and trends over time and proportion of days covered was used to measure
adherence. Frequency and percentage are presented for categorical variables. Adherence
of MOUD will be estimated by measuring proportion of days covered. As this study uses
de-identified commercial health claims data, it has been determined as not human subjects
research by the University of Kentucky’s Office of Research Integrity.
Agonist therapy with buprenorphine or buprenorphine/naloxone was the most
common treatment, representing 75.7% of those receiving treatment. Between 2011 and
2016, the percentage of individuals receiving treatment with partial agonist therapy
decreased 16.5% to 9.2%, respectively. Meanwhile, the percentage of individuals
receiving treatment with antagonist treatment increased from 0.1% in 2011 to 0.3% in
2016. In the analysis of proportion of days covered, all MOUD reported a decrease at both
180 and 365 days. In the commercial population, younger female patients were more likely
to be treated with injectable naltrexone. Specifically, in the North Central geographic
region, commercial adult patients were more likely to be treated with buprenorphine
monotherapy.
Overall, this study found a decrease in use of agonist therapy from 2011 through
2016, with an increase in use of antagonist therapy in the same time period. However, the
increase in use of antagonist therapy does not fully account for the decrease in use of
agonist therapy, suggesting that since 2011 many patients with OUD still remain untreated.

All MOUD types were analyzed and saw a decrease in proportion of days covered, as a
measure of adherence, from 2011 to 2016 putting patients at an increased risk for relapse,
further complications, emergency visits, and hospitalizations. More information is needed
about characteristics of patients who not only seek out treatment for OUD, but also
maintain their treatment overtime.

KEYWORDS: Opioid Use Disorder, Medication Assisted Treatment, Medications for
Opioid Use Disorder, Proportion of Days Covered, Agonist, Antagonist
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CHAPTER 1. INTRODUCTION
PAIN
Pain is defined as an unpleasant sensory and emotional experience associated with
actual or potential tissue damage.1 It is considered a public health problem that effects
approximately 100 million American adults and contributes significantly to morbidity,
mortality, and disability.2 Pain impacts a patient’s ability to work, engage in social
activities, and perform basic activities of daily living.

Annually, it costs society

approximately $560 billion to $635 billion in direct health care costs and loss of
productivity.2 This represents a higher annual cost than heart disease, cancer, and diabetes,
and does not even include the cost of patients in nursing homes, military personnel,
children under 18 years old, or correction inmates.2
Common medications for treatment of pain include acetaminophen, nonsteroidal
anti-inflammatory drugs, topical agents like lidocaine, capsaicin, and diclofenac, and
opioids. Patients with acute, chronic, and cancer related pain can significantly benefit from
the use of prescription opioids including morphine, codeine, oxycodone, hydrocodone, and
fentanyl for their analgesic effect.3,4,5 Opioids work by binding to the mu, kappa, and delta
receptors in the central nervous system causing inhibition of the ascending pain pathway
altering the perception of and response to pain.6 Along with their analgesic effects, opioids
target the brain’s reward system by flooding the circuit with dopamine.

This

overstimulation produces a euphoric effect that is a major cause of improper use, diversion,
dependence, and addiction.7

1

Addiction is defined as a, “primary, chronic and relapsing brain disease
characterized by an individual pathologically pursuing reward and or relief by substance
use and other behaviors.”8 Continued misuse of prescription opioids may result in
addiction and development of opioid use disorder.
OPIOID USE DISORDER
Opioid Use Disorder (OUD) and opioid overdose are pervasive public health
problems in the United States. OUD is treatable chronic brain disease defined as a pattern
of repeated opioid use that causes change in neural structure and significant impairment or
distress.9 The diagnosis of OUD is based on specific criteria over a 12-month period
including unsuccessful efforts to cut down or control use, use resulting in social problems,
failure to fulfill obligations at work, school, or home, and other criteria.10 Anyone who
uses opioids for the management of pain is at risk for developing OUD and having an
opioid overdose.
The history of opioid overdose deaths has been classified by the Centers for Disease
Control and Prevention (CDC) in three distinct waves. The first wave beginning in the
early 1990s with increased rates of opioid prescribing and death involving prescription
opioids. The second wave beginning in 2010, with opioid overdose deaths involving
heroin. The third wave beginning in 2013 with overdose deaths rising from illicitly
manufactured fentanyl and carfentanil. During the three waves from the 1990s to 2017,
approximately 400,000 people died from an overdose involving a prescription or illicit
opioid.11
Today, approximately 130 Americans die daily from a prescription, illicit, or
combination opioid overdose.11 Of the adolescent population aged 12 to 17 years old, 3.6%
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report misusing opioids. This percentage doubles among older adolescents and young
adults aged 18 to 25 years old. This opioid misuse costs $78.5 billion annually in direct
and indirect costs including the cost of healthcare, lost productivity, addiction treatment,
and criminal justice involvement.12 In response, the U.S. Department of Health and Human
Services (HHS) declared the opioid crisis a public health emergency. HHS outlined a fivepoint strategy to combat the opioid crisis, one of which is to improve access to treatment
and recovery services.13 Effective treatment of OUD can reduce the risk of opioid overdose
and help affected persons attain a healthier life.
MEDICATIONS FOR OPIOID USE DISORDER
Medications for opioid use disorder (MOUD) have been shown to be effective at
reducing OUD morbidity and mortality. They are used in combination with behavioral
therapy and are intended to normalize brain structure and function.9 MOUD can help
decrease opioid use, increase social functioning, increase retention in treatment, and
decrease deaths from overdose. They are highly effective across all population subgroups
including adolescents, older persons, pregnant women, individuals with co-occurring
disorders, and all racial, sex and gender, and socioeconomic groups.9 Two distinct
approaches to MOUD are currently used: agonist therapy with methadone or
buprenorphine, or antagonist therapy with naltrexone.7
Methadone, a full opioid receptor agonist, has been used for OUD treatment for the
past 40 years.14 It works by binding to the opioid receptors in the central nervous system
(CNS), causing inhibition of the ascending pain pathways, and altering the perception of
and response to pain.15 It eliminates withdrawal symptoms, blocks the euphoric effects of
opioids, and relieves drug cravings.15
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Methadone is offered in an oral tablet, oral solution, and an injectable form and is
taken once daily by patients in a licensed outpatient treatment program under the
supervision of a physician.15

The dose of methadone for detoxification is highly

individualized taking into account the patient’s severity of pain, patient response, prior
analgesic treatment experiences, and risk factors for addiction. An initial starting dose is
typically 20 to 30 mg when a patient shows signs of withdrawal and no signs of sedation
or intoxication. The dose is then titrated to the patient’s maintenance dose, typically 80 to
120 mg daily.16 The maintenance dose prevents opioid withdrawal symptoms for 24 hours,
inhibits cravings, and blocks the euphoric effect of opioids.16 The length of time in
methadone treatment for OUD varies from person to person, but according to the National
Institute on Drug Abuse, the minimum length of treatment should be 12 months.14 More
recently, the National Academies of Sciences, Engineering, and Medicine reported that
long-term retention on MOUD is associated with improved outcomes and lower chances
of relapse and overdose.9
Similar to other prescription and illicit opioids, methadone also has high potential
for abuse and dependence.15

Along with its addictive properties, patients taking

methadone may also experience serious adverse effects including respiratory depression,
somnolence, swelling of face, lips, tongue or throat, hives, rash, chest pain, confusion,
generalized CNS depression, or death.17 Due to these properties, when methadone is used
for OUD treatment, it can only be dispensed through a treatment program certified by the
Substance Abuse and Mental Health Services Administration (SAMHSA) where clinical
response and behavior can be monitored.15,18 Federal restrictions make it difficult to access
patient data for those using methadone for treatment of OUD.15,18
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Buprenorphine, another medication for treatment of OUD, is a partial opioid
agonist and has been available since October 2002.19 It exhibits high affinity binding to the
mu opioid receptor in the CNS, displaying mu agonist activity. It also possesses weak
kappa antagonist activity. As its analgesic effect plateaus at higher doses, it then starts to
behave like an antagonist.20 Similarly to methadone, buprenorphine is prescribed in
combination with behavioral therapy such as counseling and participation in social support
programs.19 It is the first medication used for treatment of OUD that is permitted to be
prescribed in outpatient physicians’ offices and dispensed in community pharmacies,
significantly increasing treatment access.19
Buprenorphine is effective for treatment for OUD because of its’ ability to reduce
cravings and withdrawal symptoms.19 It is offered in several dosage forms including a
buccal film, a sublingual tablet, a subcutaneous implant, and as an injection. It is either
taken daily in an outpatient treatment program or prescribed to a patient to take daily at
home by a provider who has received a waiver to prescribe buprenorphine.21 Through the
waiver process, practitioners, including physicians and more recently advanced registered
nurse practitioners and physician assistants when allowed by state law, receive an “X”
license from the DEA that specifically allows providers with extra training in addiction
treatment to prescribe buprenorphine.21
Treatment with buprenorphine occurs in three phases. The first stage, the induction
phase, takes place in a qualified physician or other practitioner’s office or certified opioid
treatment program. An initial dose of buprenorphine 2 to 4 mg daily is administered when
the patient with OUD has abstained from using opioids for at least 12 to 24 hours and is in
early withdrawal.19 This phase has the potential to put the patient into withdrawal if they
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still have opioids in their blood stream. The stabilization phase, or second phase of
buprenorphine treatment, begins when the patient has greatly reduced their use of opioids,
no longer has cravings, and experiences few side effects. The dose of buprenorphine can
be adjusted during this phase. Similarly, to methadone, there is variability between patients
in the effective dose of buprenorphine. A typical dose may range from 4 mg to 16 mg
daily.20 The maintenance phase, or final phase, occurs when the patient is stable on a dose
of buprenorphine. The length of the maintenance phase varies for each individual and
could be indefinite.19 Long-term retention on buprenorphine is associated with improved
outcomes and lower chances of relapse and overdose.9
Buprenorphine exhibits addictive analgesic effects, and therefore can be misused
and abused by patients. Naloxone is added in combination with buprenorphine to decrease
the likelihood of diversion and misuse of the drug.19 It works as a pure opioid antagonist
that competes and displaces opioids on their receptor sites.22 If the medication is misused
by patients and injected instead of used as a sublingual tablet or film, naloxone will block
the euphoric effects of buprenorphine and can precipitate withdrawal in a patient dependent
on opioids.19
One special population to note are pregnant patients. Buprenorphine monotherapy,
specifically, can be used for treatment of OUD during pregnancy. Utilizing buprenorphine
prevents opioid withdrawal symptoms, reduces risk of relapse, improves adherence to
prenatal care, and reduces the risk of obstetric complications. Compared to methadone for
treatment of OUD during pregnancy, buprenorphine has fewer drug interactions, can be
treated as an outpatient outside of an opioid treatment program, does not require as many
dose adjustments, and carries a smaller risk for neonatal abstinence syndrome. Typically,
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buprenorphine monotherapy is recommended over the combination drug product with
naloxone to avoid any potential prenatal exposure to naloxone, but recent studies
evaluating the combination product have found no adverse effects.23
Naltrexone, differing from buprenorphine and methadone, is a non-addictive,
competitive opioid antagonist, showing highest affinity for the mu receptors.24,25 It
immediately precipitates withdrawal in patients using opioids and treats OUD by blocking
any opioid from the ability to exhibit its’ rewarding euphoric effect.24 While the oral
version has been available since 1984, for the treatment of addiction to drugs such as
heroin, morphine and oxycodone, the intramuscular, long acting form was approved in
2010 for use in OUD. The injectable dosage form created a new administrative option for
patients needing help with adherence and for those who did not want to take an oral
medication daily.24
Naltrexone is initiated seven to ten days following last use of opioids.24 A naloxone
or naltrexone challenge test and urine toxicology may be performed to ensure the patients
has completed withdrawal from opioids before the long-acting injection is administered.25
The tablet form is dosed at 25mg to 50 mg once daily, but some patients may require doses
up to 100 mg daily.25 The long-acting injection is dosed as 380 mg intramuscularly into
the gluteal muscle once monthly by physician or other health care professional.25 Similar
to methadone and buprenorphine, treatment with naltrexone should be accompanied by
behavioral and counseling support.24 Differing from methadone and buprenorphine, this
treatment modality represents the first therapy for OUD that has no abuse and diversion
potential. Common adverse effects of naltrexone that patients should be aware of include
upset stomach, vomiting, diarrhea, headache, nervousness, sleep disturbances, joint pain,
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and muscle pain. Other adverse effects can include liver injury, injection site reactions,
and allergic pneumonia.25
UTILIZATION OF MEDICATIONS FOR OPIOID USE DISORDER
It is important to understand who receives medications, which medications they
receive, and how it varies by patient characteristics. This information is important to
contribute to the expansion of OUD treatment services, a national priority in the United
States.13 Recent data from the National Survey on Drug Use and Health indicated that only
22.5% of individuals with OUD receive treatment.26 A greater understanding is needed of
those individuals who receive treatment to be able to better treat other OUD patients with
similar characteristics moving forward. Studies assessing the utilization of MOUD in the
veteran, youth, and adult populations are summarized below.

1.4.1 Use in the Veteran Population
In study by Manhapra and colleagues, characteristics of veterans utilizing
buprenorphine and methadone for OUD nationally were analyzed from January 1, 2012 to
December 31, 2012. The objective of the study was to gain a better understanding of the
varying characteristics of veterans in three different OUD treatment groups. The three
groups identified were those who received buprenorphine only (n=5,670, 39.28%), those
who received methadone only (n=6,252, 43.31%), and those who received both
buprenorphine and methadone in the same year (n=2,513, 17.41%). The three groups were
compared using bivariable analyses of sociodemographic characteristics, diagnostic
characteristics, health service use, and psychotropic medication fills. Logistic regression
models were used to identify variables independently associated with receiving
buprenorphine compared to methadone, methadone compared with using buprenorphine
8

and methadone in the same year, and buprenorphine compared with using buprenorphine
and methadone in the same year. From the bivariable comparisons, the researchers found
that veterans who received buprenorphine only were younger by nearly a decade, more
likely to reside in a rural area, less likely to receive a VA pension, and more likely to have
served in Iraq or Afghanistan compared to the other two groups. They found that the
methadone only group was comprised of 40% African Americans, representing three times
the number of African Americans than the other two groups. Also, veterans with more
comorbidities were more likely to receive methadone compared to the other two groups.
From the multivariable analysis, the researchers found that those who were younger by
nearly a decade (OR 0.67; 95% CI 0.64 – 0.70), living in an urban setting (OR 0.26; 95%
CI 0.25 – 0.33), and African American race (OR 0.39; 95% CI 0.35 - 0.43), were associated
with lower odds of receiving buprenorphine compared to methadone. Researchers also
looked at medical comorbidities and other psychiatric comorbidities and medications, but
they did not identify significant difference between the three groups.27
Overall in this study of veteran patients with OUD, receiving buprenorphine or
methadone was associated with demographic characteristics rather than medical
comorbidities or psychiatric comorbidities. A limitation identified within this study is that
only full agonist and partial agonist MOUD were analyzed, and no information was
provided about antagonist therapy. Also, only the veteran population was analyzed in this
study, and so it may not be generalizable to other populations.27
Another study about veterans, published by Shiner and colleagues, researched
utilization of MOUD in those with OUD and post-traumatic stress disorder (PTSD) from
2004 to 2013. Of the 731,520 veterans with PTSD, 19,998 (2.7%) veterans were found to
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have a comorbid OUD diagnosis. From the 19,998 veterans with a diagnosis of OUD,
5,913 (29.6%) received a MOUD in the year following their initial PTSD diagnosis.
MOUD included in the study were buprenorphine, methadone, and naltrexone. The
researchers found the comorbid OUD diagnosis increased overtime from 2.5% in 2004 to
3.4% in 2013 and that MOUD utilization increased from 22.6% in 2004 to 35.1% in 2013.
More specifically, buprenorphine utilization increased from 2.0% to 22.7%, methadone
utilization decreased from 19.3% to 12.7% and naltrexone utilization increased from 2.8%
to 8.6%. They further classified veterans who were younger, living in a rural area, married,
and Caucasian as more likely to be treated with buprenorphine for OUD compared to those
who were older, living in an urban setting, unmarried, and part of a minority as more likely
to be treated with methadone. Veterans who received naltrexone were typically married,
Caucasian women with a comorbid alcohol use disorder diagnosis.28 This study builds on
the previous veterans study by including all three MOUD and clearly outlines specific
characteristics of veterans who were more likely to receive one type of MOUD compared
to another.
1.4.2 Use in the Youth Population
In a retrospective cohort study by Hadland and colleagues from January 1, 2001 to
June 30, 2014, trends in receiving buprenorphine or naltrexone among youth aged 13 to 25
years old were analyzed.29 Risk for OUD typically begins in the youth population, with
7.8% of high school seniors reporting nonmedical use of prescription opioids. Of the
20,822 youth diagnosed with OUD included in the study, 5,580 (26.8%) were dispensed a
medication for OUD within 6 months of their diagnosis. Of the 5,580 youth dispensed a
medication, 89.2% (n=4,976) were prescribed buprenorphine while 10.8% (n=604) were
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prescribed naltrexone. MOUD utilization increased more than 10 times from 3.0% in 2002
to 31.8% in 2009, and then decreased to 27.5% in 2014 in youth. From the multivariable
analysis, researchers found that the odds of receiving buprenorphine compared to
naltrexone increased from 2002 to 2010 (OR, 1.31 per year; 95% CI, 1.22 – 1.39), but the
odds of receiving naltrexone relative to buprenorphine increased from 2010 to 2014 (OR,
1.17 per year; 95% CI, 1.09 – 1.25). Overall, youth were less likely to receive a MOUD if
they were younger, female, and black or Hispanic, and low-middle neighborhood poverty
level. When youth did receive a MOUD, they were less likely to receive buprenorphine
than naltrexone if they were younger or female. Youth were more likely to receive
buprenorphine if they were from a non-metropolitan area, lower middle to low educational
level neighborhood, a high poverty level neighborhood, or from the Midwest. Naltrexone
was more commonly dispensed to younger individuals, females, those living in
metropolitan area, those with higher education level neighborhoods, and lower poverty
level neighborhoods.29 This study outlines specific characteristics of youth who were more
likely to receive buprenorphine or naltrexone for treatment of OUD.

Additional

information is needed to determine if similar trends in buprenorphine and naltrexone
utilization are observed in the adult population.
1.4.3 Use in the Adult Population
In a retrospective cohort study by Morgan and colleagues from 2010 to 2014,
prescribing patterns MOUD were analyzed in a commercially insured population.30
Specific medications investigated were injectable naltrexone, oral naltrexone, sublingual
or oral-mucosal buprenorphine in combination with naloxone, sublingual buprenorphine,
and transdermal buprenorphine.

Although transdermal buprenorphine is not FDA
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approved for opioid use disorder, it is approved for chronic pain. Researchers chose to
include this dosage form of buprenorphine in their study because they limited the data to
only patients with OUD and it appears some patients were utilizing transdermal
buprenorphine for treatment. The prevalence of OUD and proportion of diagnosed patient
months on OUD medication in the database were calculated each year. Unadjusted
descriptive statistics were utilized to compare characteristics of patients diagnosed with
OUD who received and did not receive MOUD.
From 2010 to 2014, individuals diagnosed with OUD in this population grew from
0.12% to 0.48%, while the proportion of diagnosed patient months on medication
decreased from 25% in 2010 to 16% in 2014. The population of patients with OUD was
growing, while the number of patients being treated was decreasing. Patients were more
likely to receive a MOUD if they were male, younger, and had an additional substance use
disorder. Patients with the same three characteristics were also more likely to be prescribed
injectable naltrexone over the other medications. Researchers found that after 30 days of
therapy, 52% of patients treated with injectable naltrexone, 70% of individuals treated with
oral naltrexone, 31% of individuals treated with sublingual buprenorphine/naloxone, 58%
of patients treated with sublingual buprenorphine alone, and 51% patients treated with
transdermal buprenorphine discontinued treatment. Further, a Cox proportional hazard
regression model showed that patients using injectable naltrexone, oral naltrexone,
sublingual buprenorphine, and transdermal buprenorphine were more likely to discontinue
therapy beginning > 30 days after MOUD initiation (HR = 2.17, 2.54, 1.15, 2.21, 95% CI
2.04 – 2.30, 2.45 – 2.64, 1.10 – 1.19, 2.11 – 2.33) compared with sublingual buprenorphine
in combination with naloxone.30
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In another study utilizing the adult population, Ronquest and colleagues analyzed
the relationship between buprenorphine adherence and relapse, health care utilization, and
costs in privately and publicly insured patients with OUD.31 Patients with OUD prescribed
buprenorphine between 2008 and 2014 were included in the study and followed for 12
months after their earliest outpatient pharmacy claim for buprenorphine. Adherence to
buprenorphine was measured by proportion of days covered (PDC). PDC was calculated
by the sum of day supply in the study period divided by days in the follow – up period (365
days). The researchers defined a PDC of ≥ 0.80 as adherent. Descriptive and adjusted
analyses compared relapse prevalence, utilization, and costs of adherent patients to nonadherent patients. Of those in the commercial sample (n=16,085), 37.1% were found to be
adherent, while 41.3% of those in the Medicaid sample (n= 5,688) were found to be
adherent. Total costs (pharmacy and medical) for adherent patients in the Commercial
sample ($17,519) were significantly lower than non-adherent patients ($20,294 - $24,431),
while in the Medicaid sample, total costs were not significantly different between the
groups. In conclusion, researchers found that the buprenorphine adherence in the 12
months following the earliest outpatient claim was associated with reduced odds of relapse
and reduced total healthcare costs. Non-adherent patients were found to have more
hospitalizations and emergency room visits.31 This study included new information in
comparison to previous studies on adherence to buprenorphine as treatment for OUD. It is
limited because it only analyzed one modality of MOUD, buprenorphine, and no others.
From the above studies, we have learned about some of the characteristics in
veterans, youth, and adults that show who is more likely to receive one type of MOUD
compared to another. The studies reported information on the utilization of MOUD over
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time, but only have data that goes through 2014. More information is needed on the
changes in MOUD utilization in more recent years. Only one study provides information
on adherence, through PDC, to buprenorphine following OUD diagnosis and the first
outpatient pharmacy claim. Additional information is needed on the adherence to all
MOUDs. Overall, this information will further help clinicians determine the best treatment
option for their patients based on the patient’s characteristics and which treatment option
has the best adherence for treatment success overtime.

1.5

PURPOSE AND OBJECTIVES
Relatively limited information is available about the patterns of use, adherence, and

the characteristics of those who use agonist versus antagonist therapy in the adult,
commercially insured population. Thus, the primary objective of this descriptive study to
assess trends in medications used for OUD in a population of commercially insured patients
in the United States from 2011 - 2016. Further, the secondary objectives are to describe
the demographic characteristics of those who use agonist vs. antagonist therapy, to measure
adherence to MOUD through proportion of days covered at 6 and 12 months following
initiation of therapy and to measure the odds of receiving injectable naltrexone in this
patient population compared to other forms of MOUD, including buprenorphine
monotherapy, buprenorphine in combination with naloxone, and oral naltrexone.
Although this is a descriptive study, we hypothesize that from 2011 through 2016,
there will be an increase in the utilization of injectable naltrexone compared to other types
of MOUD. In a study by Jackson and colleagues, effectiveness and cost–effectiveness of
extended release injectable naltrexone were compared to methadone and buprenorphine
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maintenance treatment in adult males ages 18 to 65 years old over 6 months. The results
show that injectable naltrexone is more costly that methadone or buprenorphine but is more
effective at discouraging opioid use while on treatment. Results suggest that injectable
naltrexone can be cost effective if health payers are willing to pay $72 per opioid free day
gained (equivalent to treating three patients with methadone for one day), because it
discourages opioid use preventing more complications in the future.32

CHAPTER 2. METHODS
DATA SOURCE
Data were obtained from individuals enrolled in the Truven Marketscan
Commercial Claims Database between January 1, 2011 and December 31, 2016. The
database contains individual level health care claims data. Information is available from
almost 115 million commercially insured patients, their spouses, and dependents from a
broad geographic area across the United States. The database provides information on
medical, dental, and prescription claims at the patient level, laboratory results, health risk
assessments, and hospital discharges.33 All study data were de-identified and anonymous,
so the study does not meet the federal definition of “human subjects research” and thus was
exempt from IRB review by the University of Kentucky’s Office of Research Integrity.
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COHORT
All individuals aged 18 years and older with an International Classification of Disease
Code (ICD) – 9 or ICD – 10 diagnosis of OUD (Appendix 3) were eligible to be included
in the cohort. The codes were not validated for accuracy in identifying patients with OUD.
Medications approved by the FDA for OUD were identified by generic product identifier
codes and classified as agonist (buprenorphine, buprenorphine/naloxone) or antagonist
(oral naltrexone and injectable naltrexone) using national drug codes. See Appendix 1.
Patients were included in the study if were at least 18 years and old and a had a prescription
claim for agonist and or antagonist therapy. All individuals under the age of 18 and without
a diagnosis of OUD were excluded from the study. Other patients excluded were those
who had a prescription claim for agonist or antagonist therapy in the 6 months prior to their
diagnosis with OUD to ensure they were receiving this medication for OUD and not for
other indications like pain or alcohol use disorder. See Figure 1.
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Figure 1. Inclusion and Exclusion Diagram for Patients with OUD

488,485 with OUD

Excluded: 7,702 patients
who were < 18 years old

Excluded: 43,863 who had
claims for agonist and
antagonist therapy 6
months prior to the OUD
diagnosis

436,920 meeting inclusion
criteria

80,482 treated with agonist
and/or antagonist therapy

356,438 untreated
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Figure 2: Timeline of Study Period
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STUDY DESIGN AND STATISTICAL ANALYSIS
This retrospective, descriptive study used administrative claims data from Truven

Marketscan Commercial Claims Database between January 1, 2011 and December 31,
2016. Demographic characteristics of interest included age, gender, geographic region,
and type of insurance coverage. Clinical characteristics of interest included diagnosis of
OUD and type of MOUD used, including extended-release naltrexone for injection, oral
naltrexone, buprenorphine in combination with naloxone, and
monotherapy.

buprenorphine

Buprenorphine monotherapy dosage forms included the buccal film,

sublingual tablet, and injection. Buprenorphine in combination with naloxone dosage
forms included the sublingual film, sublingual tablet, and buccal film. Dosage forms
excluded in this study were bulk powders, methylnaltrexone bromide injection,
18

methylnaltrexone bromide tablet, naltrexone-bupropion extended release tablet, morphinenaltrexone capsule, and the buprenorphine transdermal patch because they are not used for
treatment of opioid use disorder. Methadone was also not included in this study because
there are no pharmacy claims for it since it is administered in outpatient treatment programs
and not dispensed in pharmacies.
Descriptive analyses, including frequency and percentage for all categorical
demographic variables, were utilized to understand patterns and trends of MOUD over time
Demographic variables assessed included sex, age, geographic region, and insurance plan.
Associations between patient characteristics and type of treatment received, including
those untreated, were assessed via likelihood ratio chi-square test.

Adherence was

measured using the PDC for each continuously enrolled individual MOUD at 6 months
(180 days) and 12 months (365 days) following treatment initiation. The total number of
days covered by an MOUD were calculated from the days of supply information on
pharmacy claims regardless of gaps in therapy. PDC was calculated as sum of days covered
in the study period divided by study period days (180 days or 365 days).22 See tables 3 and
4 and appendix 2.

Multinomial logistic regression was used to estimate the odds of

receiving each type of OUD medication relative to the odds of receiving injectable
naltrexone predicted by age (reference group = 18 to 26 years old), gender (reference group
= male), geographic region (reference group = South), and insurance plan (reference group
= Preferred Provider Organization). All statistical analyses were conducted using SAS
version 9.4.
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3.0

RESULTS

3.1

DESCRIPTIVE CHARACTERISTICS
Among the 436,920 patients identified as having OUD and meeting inclusion

criteria between 2011 and 2016, 80,482 (18.4%) were treated with a medication while
356,438 (81.6%) remained untreated during the study period. Of the treated patients,
agonist therapy was the most common treatment, representing 84.0% of those receiving
treatment, antagonist therapy was utilized for treatment of 10.3% of patients, and a
combination of agonist and antagonist therapy was utilized in 5.7% of patients. Those
utilizing combination therapy, did not utilize both therapies simultaneously, but within the
same year. Males represented the majority of patients, > 50.0%, in each treated group and
the untreated group. The age group 18 to 26 years old represented the largest number of
patients treated for OUD in each medication group (buprenorphine monotherapy 38.5%,
buprenorphine/naloxone 37.1%, oral naltrexone 46.4%, injectable naltrexone 54.0%).
However, in the untreated group the largest age group represented were those older than
50 years old (27.4%). The South represents the geographic region and Preferred Provider
Organization (PPO) represents the commercial insurance type with the most patients both
treated and untreated for OUD.

All demographic variables showed evidence of a

statistically significant (p <0.0001) association with the type of treatment received,
including those who were untreated. See Table 1.
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Table 1: Descriptive Characteristics of Unique Individuals with OUD, 2011 – 2016
Total Agonist
n = 67,499

Total Antagonist
n = 8,363

Parameter Buprenorphine Buprenorphine/
Oral
Injectable
Agonist &
Monotherapy
Naloxone
Naltrexone Naltrexone Antagonist
n=6,554
n=66,945
n=7,313
n=1,050 Combination
n = 4,620

Female
Male
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18 – 26
27 – 35
36 – 50
50 +
Northeast1

3,010
(45.93%)
3,544
(54.07%)

20,785
(34.10%)
40,160
(65.90%)

2,526
(38.54%)
1,599
(24.40%)
1,550
(23.65%)
879
(13.41%)

22,597
(37.08%)
16,328
(26.79%)
15,137
(24.84%)
6,878
(11.29%)

1,183
(18.05%)

14,951
(24.53%)

Sex
3,100
372
(42.39%)
(35.43%)
4,213
678
(57.61%)
(64.57%)
Age
3,391
567
(46.37%)
(54.00%)
1,213
178
(16.59%)
(16.95%)
1,691
196
(23.12)
(18.67%)
1,005
109
(13.74%)
(10.38%)
Geographic Region
1992
301
(27.24%)
(28.67%)

Untreated
n = 356,438

1,698
(36.75%)
2,922
(63.35%)

168,470 (47.26%)

3,202
(69.31%)
657
(14.22%)
559
(12.10%)
200
(4.33%)

82,931 (23.27%)

1,422
(30.78%)

187,968 (52.75%)

53,984 (15.15%)
97,823 (27.44%)
121,700 (34.14%)

77,538
(21.75%)

Table 1 (continued): Descriptive Characteristics of Unique Individuals with OUD, 2011 – 2016
Total Agonist
Total Antagonist
n = 67,499
n = 8,363
Parameter

Buprenorphine Buprenorphine/
Oral
Injectable
Agonist &
Monotherapy
Naloxone
Naltrexone Naltrexone Antagonist
n=6,554
n=66,945
n=7,313
n=1,050 Combination
n = 4,620

South3

2,670
(40.74%)
1,702
(25.97%)

24,023
(39.42%)
8,826
(14.48%)

2,578
(35.25%)
1,192
(16.30%)

396
(37.71%)
173
(16.48%)

1,300
(28.14%)
842
(18.23%)

141,427
(39.68%)
68,473 (19.21%)

Insurance*
EPO5
67
(1.02%)
6
HMO
465
(7.09%)
7
POS
549
(8.38%)
8
PPO
4,247
(64.80%)
Other
909
(13.87%)

729
(1.20%)
5,810
(9.53%)
4,677
(7.67%)
37,931
(62.24%)
7,491
(12.29%)

89
(1.22%)
741
(10.13%)
509
(6.96%)
4,424
(60.50%)
1,246
(17.04%)

15
(1.43%)
75
(7.14%)
74
(7.05%)
688
(65.52%)
157
(14.95%)

41
(0.89%)
427
(9.24%)
396
(8.57%)
2,880
(62.34%)
687
(14.87%)

7,008 (1.97%)

West4

Untreated
n = 356,438
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36,628 (10.28%)
25,093 (7.04%)
214,183 (60.09%)
46,748 (13.12%)

Table 1 (continued): Descriptive Characteristics of Unique Individuals with OUD, 2011 –
2016
1

Northeast: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont,
New Jersey, New York, Pennsylvania
2
North Central: Indiana, Illinois, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota,
Missouri, Nebraska, North Dakota, South Dakota
3
South: Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South
Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas,
Louisiana, Oklahoma, Texas
4
West: Arizona, Colorado, Idaho, New Mexico, Utah, Nevada, Wyoming, Alaska,
California, Hawaii, Oregon, Washington
5
EPO: Exclusive Provider Organization
6
HMO: Health Maintenance Organization
7
PPO: Point of Service
8
PPO: Preferred Provider Organization

3.2

TRENDS IN MOUD UTILIZATION FROM 2011 THROUGH 2016

Of the 436,920 patients meeting inclusion criteria from 2011 through 2016, trends in
utilization of each MOUD are reported in Table 2. The rate of patients utilizing buprenorphine
monotherapy from 2011 through 2016 increased from 1.2% to 1.4%. In the buprenorphinenaloxone group, the rate of patients utilizing the MOUD from 2011 to 2016 decreased from
16.5% to 9.2%. In the injectable naltrexone group, the rate of patient utilizing the MOUD
increased from 0.1% to 0.3%. Also, the rate of oral naltrexone utilization increased from 1.1%
in 2011 to 2.0% in 2016. The rate of untreated patients decreased from 79.9% in 2011 to
86.6% in 2016. See Table 2, Figure 2, and Figure 3.
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Table 2: Patients with OUD by Year and Type of Treatment Including those Untreated

Therapy
Buprenorphine
monotherapy
BuprenorphineNaloxone
Injectable
Naltrexone

2011
1,058
(1.2%)
14,215
(16.5%)
94
(0.1%)

Year of Index OUD Diagnosis
2012
2013
2014
2015
1,182
1,028
1,280
1,145
(1.5%)
(1.5%)
(1.5%)
(2.0%)
13,249
10,416
10,492
6,875
(17.0%) (15.5%) (12.2%) (11.9%)
163
180
189
229
(0.2%)
(0.3%)
(0.2%)
(0.4%)

2016
861
(1.4%)
5,698
(9.2%)
195
(0.3%)

931
1,159
1,101
1,464
1,386
1,269
(1.1%)
(1.5%)
(1.6%)
(1.7%)
(2.4%)
(2.0%)
994
1,005
901
813
596
311
(1.2%)
(1.3%)
(1.3%)
(0.9%)
(1.0%)
(0.5%)
68,730
61,270
53,370
71,909
47,391
53,778
Untreated
(79.9%)
(78.5%) (79.7%) (83.5%) (82.2%) (86.6%)
86,022
78,028
66,996
86,147
57,622
62,112
Total
(100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%)
1
Filled both buprenorphine and naltrexone prescriptions during the follow-up period
Oral Naltrexone
Buprenorphine and
Naltrexone1
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Figure 3: Percent of Patients with OUD, Treated and Untreated, from 2011 through 2016
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Figure 4: Percent Treated OUD Patients by Year and Type of Treatment
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3.3

PROPORTION OF DAYS COVERED BY MOUD TYPE AT 6 MONTHS
Among the 6,554 patients in the buprenorphine monotherapy group, the PDC

decreased from 0.54 in 2011 to 0.41 in 2016 within the first 6 months following the first
prescription claim. Of the 66,945 patients in the buprenorphine naloxone combination
group, the PDC increased from 0.59 in 2011 to 0.60 in 2014, and then subsequently
decreased to 0.52 in 2016. Of the 7,313 patients included in the oral naltrexone group,
there was an overall decrease in PDC from 0.32 in 2011 to 0.29 in 2016. Of the 1,050
patients in the injectable naltrexone group, the PDC decreased from 0.53 in 2011 to 0.37
in 2016. Of the 5,038 patients in the combination group of agonist and antagonist therapy,
the PDC decreased from 0.47 in 2011 to 0.38 in 2016. See Table 3.
Table 3: Proportion of Days Covered at 6 months (180 Days) for those Receiving MOUD
by Medication Type, 2011 – 2016

Year

2011
2012
2013
2014
2015
2016

Year

2011
2012
2013
2014
2015
2016

Buprenorphine Monotherapy
Day
Days
PDC
Covered in Treated in 6
6 Months
Months
86,241
156,780
0.54
91,502
192,420
0.47
84,289
169,560
0.49
103,394
224,460
0.46
105,533
206,280
0.49
94,105
230,220
0.41

Buprenorphine/Naloxone
Days Covered
Days
PDC
in 6 Months
Treated in 6
Months
1,294,269
2,207,340
0.59
1,328,194
2,320,920
0.57
1,123,340
1,892,700
0.59
1,181,686
1,970,100
0.60
775,716
1,307,340
0.59
666,265
1,271,700
0.52

Injectable Naltrexone
Day
Days
PDC
Covered in Treated in
6 Months
6 Months
5,254
9,900
0.53
8,428
21,960
0.38
11,256
30,420
0.37
14,321
34,380
0.41
16,720
42,480
0.39
18,512
49,860
0.37

Oral Naltrexone
Days Covered Days Treated
in 6 Months
in 6 Months

PDC

42,566
55,462
54,962
78,173
80,217
91,078

0.32
0.30
0.30
0.30
0.32
0.29
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132,660
184,320
181,800
253,980
248,940
314,640

Table 3 (continued): Proportion of Days Covered at 6 months (180 Days) for those
Receiving MOUD by Medication Type, 2011 – 2016

Year

2011
2012
2013
2014
2015
2016

3.4

Agonist & Antagonist Therapy
Days
Days
PDC
Covered
Treated
in 6
in 6
months
Months
63,050
132,300 0.47
79,887
167,400 0.47
76,694
167,760 0.45
66,075
154,440 0.42
53,040
128,160 0.41
31,756
81,540
0.38

PROPORTION OF DAYS COVERED BY MOUD TYPE AT 12 MONTHS
Among the 6,554 patients in the buprenorphine monotherapy group, the PDC

decreased from 0.45 in 2011 to 0.26 in 2016 within the first 12 months following the first
prescription claim. Of the 66,945 patients in the buprenorphine naloxone combination
group, the PDC decreased from 0.47 in 2011 to 0.35 in 2016. The 7,313 patients included
in the oral naltrexone group, saw an overall decrease in PDC from 0.19 in 2011 to 0.15 in
2016. Of the 1,050 patients in the injectable naltrexone group, the PDC decreased from
0.34 in 2011 to 0.20 in 2016. Of the 5,038 patients in the combination group of agonist
and antagonist therapy, the PDC decreased from 0.39 in 2011 to 0.25 in 2016. See Table
4.
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Table 4: Proportion of Days Covered at 12 Months (365 Days) for those Receiving
MOUD Treatment by Medication Type, 2011 – 2016

Year

2011
2012
2013
2014
2015
2016

Year

2011
2012
2013
2014
2015
2016

Year

2011
2012
2013
2014
2015
2016

Buprenorphine Monotherapy
Days
Days
PDC
Covered in Treated
12 Months in 12
Months
143,325
317,915
0.45
138,661
390,185
0.35
137,375
343,830
0.39
167,316
455,155
0.36
165,847
418,290
0.39
123,397
466,835
0.26

Buprenorphine/Naloxone
Days Covered in
Days
PDC
12 Months
Treated in
12 Months

Injectable Naltrexone
Days
Days
PDC
Covered in Treated
12 Months in 12
Months
7,156
20,075
0.35
10,237
44,530
0.23
13,750
61,685
0.22
17,601
69,715
0.25
22,681
86,140
0.26
20,999
101,105 0.21

Oral Naltrexone
Days Covered in
Days Treated
12 Months
in 12 Months

PDC

52,191
65,148
65,924
92,721
98,457
99,255

0.19
0.17
0.18
0.18
0.19
0.15

2,103,540
2,064,500
1,822,672
1,848,472
1,278,397
901,092

Agonist & Antagonist Therapy
Days
Days
PDC
Covered
Treated
in 12
in 12
months
Months
103,186
268,275 0.39
128,871
339,450 0.37
123,661
340,180 0.36
103,827
313,170 0.33
86,625
259,880 0.33
42,440
165,345 0.25
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4,475,995
4,706,310
3,837,975
3,994,925
2,650,995
2,578,725

269,005
373,760
368,650
515,015
504,795
638,020

0.47
0.43
0.47
0.46
0.48
0.35

3.5

PREDICTORS OF RECEIVING AN MOUD TYPE
When determining the odds of receiving a type of MOUD, injectable naltrexone

was used as the reference group as well as age 18 to 26 years old, male sex, PPO insurance
plan, and the south geographic region. All individuals greater than 26 years old had higher
odds of receiving buprenorphine monotherapy, buprenorphine naloxone, and oral
naltrexone, versus injectable naltrexone, than did individuals aged 18 to 26 years old.
Females had greater odds of receiving buprenorphine monotherapy and oral naltrexone,
versus injectable naltrexone, than did males. Patients with health maintenance organization
insurance had higher odds of receiving buprenorphine in combination with naloxone and
oral naltrexone, versus injectable naltrexone, than patients with preferred provider
organization insurance. Patients in the north central and northeast region were less likely
to receive buprenorphine monotherapy versus injectable naltrexone, than did patients in
the south geographic region. Patients living in the west geographic region, were more
likely to receive buprenorphine monotherapy versus injectable naltrexone than patients in
the south geographic region. See Table 5.
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Table 5: Odds of an Individual Receiving a Type of MOUD Therapy, 2011- 2016
Type of MOUD therapy (Injectable Naltrexone –
Reference Group)
Buprenorphine
monotherapy
OR (95% CI)

Buprenorphinenaloxone
OR (95% CI)

Oral naltrexone
OR (95% CI)

Age
18 – 26 (Reference Group)
27-35
36-50
> 50

2.03 (1.68, 2.45)
1.74 (1.45, 2.08)
1.71 (1.37,2.13)

2.32 (1.95, 2.77)
1.93 (1.63,2.28)
1.54 (1.25,1.89)

1.18 (0.98,1.45)
1.44 (1.21,1.72)
1.44 (1.15,1.79)

Sex
Male (Reference Group)
Female

1.48 (1.29,1.70)

0.92 (0.81, 1.05)

1.33 (1.15,1.52)

Insurance
PPO (Reference Group)
EPO
HMO
POS
Other

0.84 (0.47,1.45)
0.94 (0.72,1.22)
1.28 (0.99,1.65)
0.98 (0.81,1.19)

1.06 (0.63,1.78)
1.49 (1.17,1.91)
1.19 (0.9641.53)
0.88 (0.74,1.05)

0.98 (0.56,1.70)
1.53 (1.18,1.97)
1.09 (0.84,1.42)
1.21 (1.00,1.47)

Geographic Region
South (Reference Group)
North central
Northeast
West

0.80 (0.65,0.97)
0.56 (0.47,0.66)
1.58 (1.30,1.93)

1.22 (1.02, 1.47)
0.75 (0.64, 0.88)
0.90 (0.75,1.08)

1.26 (1.04,1.54)
0.97 (0.82,1.14)
1.06 (0.87,1.28)

Independent variables

4.0

DISCUSSION

4.1

GENERAL
Opioid use disorder is a growing epidemic within the United States. The analysis

demonstrates that the use of evidence- based medication therapies has not kept pace with
increase in OUD diagnosis and many patients are left untreated. In this retrospective,
descriptive study, I found that 81.6% of patients remain untreated. Only about one- fifth
or 18.4% of individuals with a diagnosis of OUD received medication treatment which is
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approximately in line with recent data from the National Survey on Drug Use and Health
indicating that in 2016, only 22.5% of individuals with OUD received treatment.26 Agonist
therapy with buprenorphine or buprenorphine/naloxone was the most common treatment,
representing 75.7% of those receiving treatment. Between 2011 and 2016, the percentage
of individuals receiving treatment with partial agonist therapy decreased 16.5% to 9.2%,
respectively. Meanwhile, the percentage of individuals receiving treatment with injectable
antagonist treatment increased from 0.1% in 2011 to 0.3% in 2016. Extended-release
injectable naltrexone was FDA approved for OUD in 2010 and may account for this
increase in use, but the increase in use of antagonist therapy is not great enough to offset
the decline in agonist therapy treatment.
Adherence to MOUD was measured by proportion of days covered at 180 days and
365 days following the first pharmacy claim for a MOUD. In the first analysis at 180 days,
all MOUD reported a decrease in proportion of days covered from 2011to 2016. More
specifically, the injectable naltrexone group showed the largest decrease from 0.53 PDC in
2011 to 0.37 PDC in 2016 likely putting them at increased risk of relapse compared to other
MOUD within the first 6 months. In the second analysis at 365 days, all MOUD reported
a decreased in PDC from 2011 to 2016. The buprenorphine monotherapy group decreased
from 0.45 PDC in 2011 to 0.26 PDC in 2016, putting these patients at increased risk of
relapse compared to other MOUD within in the first 12 months.
All demographic variables showed evidence of a statistically significant (p
<0.0001) association with the type of treatment received, including those who were
untreated. Age, sex, geographic region, and insurance plan type all contribute towards the
type of MOUD treatment a patient receives or if they remain untreated.
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In the multivariate analysis study by Manhapra, veterans were less like to receive
buprenorphine if they were in a younger age group, living in an urban area, and African
American race. Although I cannot compare our results directly to this study, I found a
difference in the commercially insured patients, younger patients were more likely to
receive injectable naltrexone. In the other study of veterans by Shiner and colleagues, an
increase was found in use buprenorphine for treatment of OUD from 2.0% in 2004 to
22.7% in 2013 and an increase in naltrexone from 2.8% in 2004 to 8.6% in 2013. In the
commercial population from this study, overall, there was a decrease in use of
buprenorphine and buprenorphine naloxone from 2011 to 2013 and a continued decrease
in use until 2016, but a similar increase in use of naltrexone from 2011 to 2013 with
continued increased until 2016.

Veterans were more likely to be treated with

buprenorphine if they were younger, living in a rural area, married, and Caucasian. Based
on the variables that studied in the commercial population, I found that younger patients
were more likely to be treated with injectable naltrexone. Veterans were more like to be
treated with naltrexone if they were married, Caucasian, women, and had comorbid alcohol
use disorder. Of the variables studied in the commercial population, I found similar results
that females were more likely to be treated with injectable naltrexone.
In the multivariate analysis by Hadland and colleagues from January 1, 2001 to
June 30, 2014, youth were at an increased odd of receiving buprenorphine from 2002 to
2010 but switched to an increased odd of receiving naltrexone from 2010 to 2014.
Comparing this to the commercial adult population, an increase in utilization of both
injectable and oral naltrexone was observed from 2011 through 2014, with continued
increase in utilization to 2016. Extended-release injectable naltrexone was FDA approved
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for OUD in 2010 and may account for this increase in use. Youth were more likely to
receive buprenorphine if they were from a non-metropolitan area, lower middle class, high
poverty, and from the Midwest. Although this cannot be directly compared to my study, I
did find that commercial adult patients were more likely to be treated with buprenorphine
monotherapy in the North Central geographic region which is equivalent to the Midwest
region. Youth treated with naltrexone for OUD were younger, female, living in a metro
area, and had a high education level. Similar results were found in the commercial adult
population where younger females were more likely to be treated with injectable
naltrexone.

4.2

LIMITATIONS
Results from this commercially insured population may not be representative of the

OUD population at large. Individuals with OUD receiving agonist therapy with methadone
at certified opioid treatment programs (OTPs) are not included in administrative claims
data. Other patients that are excluded from the results are those who pay cash for their
medication. The data for study relies on the provider assessment, diagnosis, and properly
coding ICD – 9 and ICD – 10 codes for OUD. No formal research assessment is included
to confirm proper diagnosis of OUD. The proportion of days covered calculation is based
on prescription fills and reported day supply, but no information was available to determine
if the patient actually took their medication for OUD. Limited demographic characteristics
were analyzed. Others to consider include race, education level, income level, other
comorbid substance use disorder, and mental illness history. Finally, this study was limited
to individuals with commercial insurance coverage and results may not be generalizable to
patients with other types of coverage or with no insurance coverage.
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5.0

CONCLUSION
Overall, this study found a decrease in use of agonist therapy from 2011 through

2016, with an increase in use of antagonist therapy in the same time period. This trend is
in line with the hypothesis that the utilization of injectable naltrexone would increase from
2011 to 2016. However, the increase in use of antagonist therapy does not fully account
for the decrease in use of agonist therapy, suggesting that since 2011 many patients with
OUD still remain untreated. This study adds the current literature published on veterans,
youth, and adults. All MOUD types were analyzed and saw a decrease in proportion of
days covered, as a measure of adherence, from 2011 to 2016 putting patients at an increased
risk for relapse, further complications, emergency visits, and hospitalizations. Age, sex,
type of insurance plan, and geographic region contribute toward which MOUD a patient
receives, but more patient characteristics need to be analyzed in the future.

More

information is needed about characteristics of patients who not only seek out treatment for
OUD, but also maintain their treatment overtime.
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APPENDICES
APPENDIX A. NATIONAL DRUG CODES (NDC) AND FREQUENCY OF CLAIMS
FOR MOUD
Buprenorphine Monotherapy
NDC Number

Frequency

00054017613

18832

00054017713

106003

00093537856

2078

00093537956

5710

00228315303

7188

00228315603

1940

00378092393

1794

00378092493

7506

12496075701

64

12496075705

14

12496127802

238

12496131002

1016

21695051510

6

42023017905

3

50383092493

7541

50383093093

30412

55390010010

3

63481016160

205

63481020760

310

63481034860

262

63481051960

82

63481068560

80
35

63481082060

44

63481095260

77

68308020830

178
Buprenorphine/Naloxone

NDC Number

Frequency

00054018813

8176

00054018913

41290

00093572056

915

00093572156

7631

00228315403

10724

00228316473

2104

00228315503

55949

00228315573

10845

00406192303

1

00406192403

11

12496120201

353

12496120203

134520

12496120401

58

12496120403

27025

12496120801

2906

12496120803

1115833

12496121201

29

12496121203

13877

12496128302

40309

12496130602

224206

16590066630

2

42291017430

133
36

42291017530

768

43063018430

12

50383028793

691

50383029493

91

52959030430

1

52959074930

1

54123011430

102

54123091430

8449

54123092930

460

54123095730

46568

54123098630

1651

54569573900

8

54569639900

6

54868570700

1

54868570701

1

54868575000

1

55700014730

1

59385001201

8

59385001230

342

59385001401

36

59385001430

3040

59385001601

15

59385001630

594

60429058630

31

60429058730

86

65162041503

85365

65162041603

14166
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Injectable Naltrexone
NDC Number

Frequency

63459030042

4

65757030001

15736

Oral Naltrexone
NDC Number

Frequency

00185003901

130

00185003930

27

00406117001

3387

00406117003

7651

0055509201

9462

00555090202

1386

16729008101

983

16729008110

10076

42291063230

1

473305032683

1405

47335032688

1735

51224020630

1063

51224020650

1182

51285027501

6

52152010530

2

6808409121

3

68094085362

1
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APPENDIX B. PROPORTION OF DAYS COVERED (PDC) CALCULATION
COVERED DAYS IN THE STUDY PERIOD

PDC = DAYS IN THE STUDY PERIOD (180 OR 365 DAYS)

APPENDIX C. INTERNATIONAL CLASSIFICATION OF DISEASE CODES (ICD – 9
AND ICD – 10) TO IDENTIFY OPIOID USE DISORDER
ICD code

Version

Label

30400

ICD - 9

30401

ICD – 9

30402

ICD – 9

30403

ICD - 9

F1110

ICD – 10

F11120

ICD – 10

F11121

ICD – 10

F11122

ICD – 10

F11129

ICD – 10

F1114

ICD – 10

F11150

ICD – 10

F11151

ICD - 10

F11159

ICD – 10

Opioid Type Dependence
Unspecific Use
Opioid Dependence
Continuous
Opioid Dependence
Episodic
Opioid Type Dependence
Remiss
Opioid abuse,
uncomplicated
Opioid abuse with
intoxication
Opioid abuse with
intoxication delirium
Opioid abuse with
intoxication with
perceptual disturbance
Opioid abuse with
intoxication, unspecified
Opioid abuse with opioid –
induced mood disorder
Opioid abuse with opioid
induced psychotic disorder
with delusions
Opioid abuse with opioid –
induced psychotic disorder
with hallucinations
Opioid abuse with opioid
induced psychotic disorder,
unspecified
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F11181

ICD – 10

F11182

ICD – 10

F11188

ICD – 9

F1119

ICD – 10

F1120

ICD – 10

F1121

ICD – 10

F112220

ICD – 10

F11221

ICD – 10

F11222

ICD – 10

F11229

ICD – 10

F1123

ICD – 10

F1124

ICD – 10

F11250

ICD – 10

F112151

ICD – 10

F11259

ICD – 10

F11281

ICD – 10

F11282

ICD – 10

Opioid abuse with opioidinduced sexual dysfunction
Opioid abuse with opioid –
induced sleep disorder
Opioid abuse with opioid –
induced disorder
Opioid abuse with
unspecified opioid –
induced disorder
Opioid dependence,
uncomplicated
Opioid dependence, in
remission
Opioid dependence with
intoxication,
uncomplicated
Opioid dependence with
intoxication delirium
Opioid dependence with
intoxication with
perceptual disturbance
Opioid dependence with
intoxication, unspecified
Opioid dependence with
withdrawal
Opioid dependence with
opioid-induced mood
disorder
Opioid dependence with
opioid-induced psychotic
disorder with delusions
Opioid dependence with
opioid-induced psychotic
disorder with
hallucinations
Opioid dependence with
opioid-induced psychotic
disorder, unspecified
Opioid dependence with
opioid-induced sexual
dysfunction
Opioid dependence with
opioid-induced sleep
disorder
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F11288

ICD – 10

F1129

ICD – 10

F1190

ICD – 10

F11920

ICD – 10

F11921

ICD – 10

F11922

ICD – 10

F11929

ICD – 10

F1193

ICD – 10

F1194

ICD – 10

F11950

ICD – 10

F11951

ICD – 10

F11959

ICD – 10

F11981

ICD – 10

F11988

ICD – 10

F1199

ICD – 10

Opioid dependence with
other opioid-induced
disorder
Opioid dependence with
unspecified opioid-induced
disorder
Opioid use, unspecified,
uncomplicated
Opioid use, unspecified
with intoxication,
uncomplicated
Opioid use, unspecified
with intoxication delirium
Opioid use, unspecified
with intoxication with
perceptual disturbance
Opioid use, unspecified
with intoxication,
unspecified
Opioid use, unspecified
with withdrawal
Opioid use, unspecified
with opioid-induced mood
disorder
Opioid use, unspecified
with opioid-induced
psychotic disorder with
delusions
Opioid use, unspecified
with opioid-induced
psychotic disorder with
hallucinations
Opioid use, unspecified
with opioid-induced
psychotic disorder,
unspecified
Opioid use, unspecified
with opioid-induced sleep
disorder
Opioid use, unspecified
with other opioid-induced
disorder
Opioid use, unspecified
with unspecified opioidinduced disorder
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